ADA 2017

News
J&J

J&J diabetes drug hit by amputation risk

The CANVAS trial was supposed to provide definitive cardiovascular safety data for Janssen’s Invokana (canagliflozin) in type 2 diabetes – and while it has succeeded in this regard, investi